Eagle Pharmaceuticals Reports Third Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 31c, Revenues Miss
November 12, 2019 6:53 AM ESTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $0.26, $0.31 worse than the analyst estimate of $0.57. Revenue for the quarter came in at $41.15 million versus the consensus estimate of $48.49 million.
Invested $12 million in research and development and external legal costs to advance Eagles pipeline.Eagles Japanese marketing partner, SymBio Pharmaceuticals Limited, submitted a New Drug Application (NDA) for TREAKISYM, bendamustine ready-to-dilute liquid formulation, in Japan in September. Approval is expected in Q4 2020, which would trigger a $5 million milestone payment to Eagle. Potential payments to Eagle could reach $10 to $25 million per year in royalties and... More